FDA Approves Shock Absorber You Can Actually Implant in Your Knee
Published Date: 6/29/2026
Rule
Summary
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Medial Knee Shock Absorber Now Class II
The FDA classified the medial knee implanted shock absorber as a Class II device with special controls, effective June 29, 2026 (classification applicable April 10, 2023). FDA says this reduces regulatory burdens and is intended to enhance patient access and speed availability of this knee implant.
Manufacturers Must Use 510(k) Pathway
The medial knee implanted shock absorber is subject to premarket notification under section 510(k), meaning device sponsors must submit a 510(k) to market this Class II device unless FDA later exempts it. FDA also notes a De Novo-classified device can serve as a predicate for future 510(k) submissions.
Required Testing, Training, and Labeling Controls
FDA codified special controls for the device that require: clinical data showing improved knee function and relevant adverse events; non-clinical performance testing (mechanical function, durability, fretting/corrosion, static strength, wear, fatigue, worst-case range of motion); biocompatibility; sterility and pyrogenicity data; reprocessing validation for reusable components; shelf-life demonstration; a training program for safe implantation; and labeling that includes validated reprocessing instructions and a shelf life.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2026-13092, Technical Guidelines for the Production of Regenerative Agricultural Biofuel Feedstocks
Starting July 29, 2026, farmers growing crops for biofuels will follow new, clearer rules to measure and report how their farming practices reduce carbon emissions. These updated guidelines help track the environmental impact from farm to fuel, making it easier to prove greener biofuel production. This affects farmers, biofuel producers, and supply chain folks, aiming to boost cleaner energy while keeping reporting fair and accurate.
Next: C1-2026-10036, Real Estate Lending Escrow Accounts
Starting soon, banks and lenders must follow new rules about real estate escrow accounts, which hold money for things like taxes and insurance. These changes mainly affect lenders and borrowers by making escrow handling clearer and more consistent. The updated rules kick in right away, aiming to protect your money and keep things fair.